*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · preclinical | PMID 41490200 |
| 2024 | Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats Journal of Huntington's disease · preclinical | PMID 38489193 |
| 2021 | Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies Annals of medicine and surgery (2012) · preclinical | PMID 34703584 |
| 2021 | AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway Brain sciences · preclinical | PMID 34827486 |
| 2018 | Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies Neuroscience and biobehavioral reviews · preclinical | PMID 29733881 |
| 2015 | The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases Progress in neurobiology · preclinical | PMID 25455861 |
| 2015 | Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure Frontiers in cellular neuroscience · preclinical | PMID 25674052 |
| 2015 | The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease Journal of Alzheimer's disease : JAD · preclinical | PMID 25649658 |
| 2014 | The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system The Journal of pharmacology and experimental therapeutics · preclinical | PMID 25187433 |
| 2013 | Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents The Journal of pharmacology and experimental therapeutics · preclinical | PMID 23055539 |
Dihexa (Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)). Angiotensin IV analogue / HGF-c-Met pathway modulator. Reported to potently promote synaptogenesis (preclinically) — orders of magnitude more potent than BDNF in some assays.
Commonly discussed uses: cognitive enhancement research (preclinical), neurodegeneration research. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: Angiotensin IV analogue / HGF-c-Met pathway modulator. Reported to potently promote synaptogenesis (preclinically) — orders of magnitude more potent than BDNF in some assays.
Reported considerations: no human safety data, theoretical concern: c-Met pro-growth signalling and malignancy. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. No human safety data. Theoretical oncogenic concern from pro-growth mechanism. Research compound only. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low research-defined, typical no established human dose (8-20mg anecdotal, unvalidated), high unknown safe ceiling. Administration: oral, subcutaneous, transdermal (anecdotal). Half-life: not well characterised in humans.
Australian status: Not ARTG-registered; research. No human safety data. Theoretical oncogenic concern from pro-growth mechanism. Research compound only. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research-defined (poorly water soluble); storage: refrigerated/frozen.
Commonly discussed combinations (anecdotal for unapproved compounds): research compound; no validated protocols. Stacking increases interaction/safety uncertainty.